Compare Expensify Inc (EXFY) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Medpace Holdings Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 80.5× Expensify Inc's market cap, and Expensify Inc is more actively traded (456,102 versus 223,093). Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Medpace Holdings Inc for 14 Days on average.
| EXFY | MEDP | |
|---|---|---|
Market Cap | $208.82M | $16.82B |
Volume | 456,102 | 223,093 |
Sector | Technology | Health |
52-Week High | $2.72 | $630.19 |
52-Week Low | $0.75 | $393.42 |
Typical Hold Time | 41 Days | 14 Days |
Enterprise Value | $148.44M | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.40, up 5.73% today, showing technical bullish momentum. The company reported mixed quarterly results with recent beats but remains unprofitable with negative margins. Recent business developments include strategic AI integrations and European expansion of its corporate card program, signaling growth initiatives. Analyst sentiment is cautiously optimistic with a 50% buy rating and $13.75 consensus target, though fundamentals show continued losses.
The outlook remains speculative given persistent negative profitability despite revenue stabilization. Investment opportunity hinges on successful execution of AI integrations and international expansion driving future profitability. Key risks include competitive pressure in expense management software and the challenge of achieving sustainable positive earnings amid ongoing operational losses.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
